Intervention Protocol

You have free access to this content

Rilpivirine versus efavirenz for initial therapy in treatment-naive, HIV-1-infected patients

  1. Adeniyi Oluwaseun Ogunjale1,*,
  2. Charles I Okwundu2

Editorial Group: Cochrane HIV/AIDS Group

Published Online: 18 JAN 2014

Assessed as up-to-date: 22 DEC 2013

DOI: 10.1002/14651858.CD010935

How to Cite

Ogunjale AO, Okwundu CI. Rilpivirine versus efavirenz for initial therapy in treatment-naive, HIV-1-infected patients (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD010935. DOI: 10.1002/14651858.CD010935.

Author Information

  1. 1

    Stellenbosch University, Communty Health Division, Faculty of Medicine and Health Sciences, Tygerberg, South Africa

  2. 2

    Stellenbosch University, Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences, Tygerberg, South Africa

*Adeniyi Oluwaseun Ogunjale, Communty Health Division, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.

Publication History

  1. Publication Status: New
  2. Published Online: 18 JAN 2014



Additional references

Cohen 2010
  • Cohen C, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, et al. Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naive, HIV-1-infected patients. Journal of the International AIDS Society 2010;13:1-18.
DAIDS 2009
  • Division of AIDS. Table for Grading the Severity of Adult and Pediatric Adverse Events. National Institutes of Health, Bethesda, Maryland December 2004.
Ford 2010
  • Ford N, Mofenson L, Kranzer K, Medu L, Frigati L, Mills EJ, et al. Safety of efavirenz in first-trimester of pregnancy: A systematic review and meta-analysis of outcomes from observational cohorts. AIDS 2010;24(10):1461–1470.
Ford 2011
  • Ford N, Lee J, Andrieux-Meyer I, Calmy A. Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings. HIV/AIDS - Research and Palliative Care April 2011;3:35-44.
Gilks 2006
  • Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Sutherland D, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet August 2006;368 (9534):505-510.
Higgins 2003
Higgins 2011
  • Higgins JPT, Green S. Cochrane Handbok for Systematic Review of Intervention. The Cochrane Collaboration. Wiley, 2011:276-293.
Hosein 2010
  • Hosein SR. Rilpivirine vs. Efavirenz. The XVIII international AIDS conference. 18-23 July, 2010:Abstract.
Janssen 2005
  • Janssen PA, Lewi PJ, Arnold E, Daeyaert F, de Jonge M, Heeres J, et al. In search of a novel anti-HIV drug: Multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidine]amino] benzonitrile (R278474, rilpivirine). Journal of Medical Chemistry 2005;48(1901-1909):6.
Meintjes 2012
  • Meintjes G, Maartens G, Boulle A, Conradie F, Goemaere E, Hefer E, et al. Guidelines for antiretroviral therapy in adults. South African HIV Clinician Society 2012;13(1608-9693):114-131.
Mills 2006
  • Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachilis B, Wu P, et al. Adherence to HAART: A systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Medicine 2006;3:11.
Pozniak 2007
  • Pozniak A, Morales-Ramirez J, Mohap L, Santoscoy M, Chetchotisakd P, Hereygers M, et al. 48-week primary analysis of trial TMC278-C204. 14th Conference on Retroviruse. 2007; Vol. Abstract:1.
  • Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS report on the global AIDS epidemic. UNAIDS 2012:8.
WHO 2011
  • World Health Organization. Report on global HIV/AIDS response. 2011.
WHO 2013
  • World Health Organisation. Consolidated guidelines on the use of anti-retroviral drugs for treating and preventing HIV infection. WHO guideline June 2013:27-33.